Literature DB >> 10078501

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

D Robinson1, M G Woerner, J M Alvir, R Bilder, R Goldman, S Geisler, A Koreen, B Sheitman, M Chakos, D Mayerhoff, J A Lieberman.   

Abstract

BACKGROUND: We examined relapse after response to a first episode of schizophrenia or schizoaffective disorder.
METHODS: Patients with first-episode schizophrenia were assessed on measures of psychopathologic variables, cognition, social functioning, and biological variables and treated according to a standardized algorithm. The sample for the relapse analyses consisted of 104 patients who responded to treatment of their index episode and were at risk for relapse.
RESULTS: Five years after initial recovery, the cumulative first relapse rate was 81.9% (95% confidence interval [CI], 70.6%-93.2%); the second relapse rate was 78.0% (95% CI, 46.5%-100.0%). By 4 years after recovery from a second relapse, the cumulative third relapse rate was 86.2% (95% CI, 61.5%-100.0%). Discontinuing antipsychotic drug therapy increased the risk of relapse by almost 5 times (hazard ratio for an initial relapse, 4.89 [99% CI, 2.49-9.60]; hazard ratio for a second relapse, 4.57 [99% CI, 1.49-14.02]). Subsequent analyses controlling for antipsychotic drug use showed that patients with poor premorbid adaptation to school and premorbid social withdrawal relapsed earlier. Sex, diagnosis, obstetric complications, duration of psychotic illness before treatment, baseline symptoms, neuroendocrine measures, methylphenidate hydrochloride challenge response, neuropsychologic and magnetic resonance imaging measures, time to response of the initial episode, adverse effects during treatment, and presence of residual symptoms after the initial episode were not significantly related to time to relapse.
CONCLUSIONS: There is a high rate of relapse within 5 years of recovery from a first episode of schizophrenia and schizoaffective disorder. This risk is diminished by maintenance antipsychotic drug treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078501     DOI: 10.1001/archpsyc.56.3.241

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  253 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  The field of schizophrenia: strengths, weaknesses, opportunities, and threats.

Authors:  John M Kane; Barbara Cornblatt; Christoph U Correll; Terry Goldberg; Todd Lencz; Anil K Malhotra; Delbert Robinson; Philip Szeszko
Journal:  Schizophr Bull       Date:  2011-11-18       Impact factor: 9.306

Review 4.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

5.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

Review 6.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 7.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials.

Authors:  Miguel Camacho-Gomez; Pere Castellvi
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

9.  Effectiveness of Community Treatment Order in Patients with a First Episode of Psychosis: A Mirror-Image Study.

Authors:  Emmanuelle Levy; Sally Mustafa; Kanza Naveed; Ridha Joober
Journal:  Can J Psychiatry       Date:  2018-08-05       Impact factor: 4.356

10.  Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome.

Authors:  Christoph U Correll; Julie B Penzner; Anne M Frederickson; Jessica J Richter; Andrea M Auther; Christopher W Smith; John M Kane; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2007-05-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.